Sino Biopharmaceutical (1177) Stock Overview
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
1177 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeSino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.43 |
| 52 Week High | HK$9.12 |
| 52 Week Low | HK$3.74 |
| Beta | 0.64 |
| 1 Month Change | -10.10% |
| 3 Month Change | -16.20% |
| 1 Year Change | 38.87% |
| 3 Year Change | 34.41% |
| 5 Year Change | -36.04% |
| Change since IPO | 19,894.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1177 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.2% | -1.4% | 1.1% |
| 1Y | 38.9% | 28.7% | 19.7% |
Return vs Industry: 1177 exceeded the Hong Kong Pharmaceuticals industry which returned 30.5% over the past year.
Return vs Market: 1177 exceeded the Hong Kong Market which returned 20.3% over the past year.
Price Volatility
| 1177 volatility | |
|---|---|
| 1177 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 1177 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1177's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 21,435 | Eric Tse | www.sbpgroup.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand.
Sino Biopharmaceutical Limited Fundamentals Summary
| 1177 fundamental statistics | |
|---|---|
| Market cap | HK$96.91b |
| Earnings (TTM) | HK$2.70b |
| Revenue (TTM) | HK$36.64b |
Is 1177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1177 income statement (TTM) | |
|---|---|
| Revenue | CN¥31.83b |
| Cost of Revenue | CN¥5.71b |
| Gross Profit | CN¥26.13b |
| Other Expenses | CN¥23.78b |
| Earnings | CN¥2.34b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 82.07% |
| Net Profit Margin | 7.36% |
| Debt/Equity Ratio | 38.0% |
How did 1177 perform over the long term?
See historical performance and comparisonDividends
Does 1177 pay a reliable dividends?
See 1177 dividend history and benchmarks| Sino Biopharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 24 2026 |
| Dividend Pay Date | Jul 20 2026 |
| Days until Ex dividend | 45 days |
| Days until Dividend pay date | 71 days |
Does 1177 pay a reliable dividends?
See 1177 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 14:30 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sino Biopharmaceutical Limited is covered by 34 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Bo Yu | China International Capital Corporation Limited |